Do you want to read an article? Please log in or register.
Review of the Impact of Weight Loss and Body Mass Index in Clinical Trials of Nintedanib in Interstitial Lung Disease
Interstitial Lung Disease
Related content
RECOMMENDED
Interstitial Lung DiseasePneumonia
Inflammatory activity as a predictor of clinical deterioration in interstitial pneumonia with autoimmune features: a comparative cohort study with connective tissue disease-associated interstitial lung disease
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis
Ulutaş F, Yiğit N, Güngör G, Çobankara V
doi: 10.1177/17534666261465583
Interstitial Lung DiseasePulmonary Fibrosis
Pamufetinib (TAS-115) for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A double-blind, multicenter, phase 2b Clinical Trial
Am J Respir Crit Care Med
Okuda R, Nishioka Y, Kondoh Y, Tsubouchi K, Okamoto M, Nishiyama O, Sato S, Oishi K, Ishikawa N, Chiba H, Miyazaki Y, Homma S, Ogura T, Inoue Y, Azuma A
doi: 10.1093/ajrccm/aamag125
RECOMMENDED
Interstitial Lung Disease
Clinical Practice Guideline for the diagnosis of Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD) in patients with Common Variable Immunodeficiency Disorders (CVID) - an ERS Clinical Research Collaboration
★ 3
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Bintalib HM, van de Ven AAJM, Rojas-Reyes MX, Davidsen JR, Hanitsch LG, Cinetto F, Malphettes M, Van Montfrans JM, Jacob J, Milito C, Haerynck F, Strauss F, Cool C, Calderon-Jaramillo M, Lopez-Mujica X, Maglione P, Trujillo-Martin MM, ESID Clinical Guideline Working Party; ERS e-GLILDnet Clinical Research Collaboration, Fevang B, Routes J, Hurst JR, Warnatz K
doi: 10.1183/13993003.02224-2025
RECOMMENDED
Interstitial Lung DiseasePulmonary FibrosisLung Cancer
Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Pagliaro R, Della Monica P, D'Agnano V, Schiattarella A, D'Orologio A, Medusa PM, Stella GM, Colapietra F, Perrotta F, Bianco A, Di Domenico M, Scialò F
doi: 10.3390/jcm15030996
Lung Cancer
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO)
Lung Cancer
Borghetti P, D'Angelillo R, Facheris G, Borghesi A, Bruni A, Ceruti P, Ferrari K, Filippi AR, Ramella S, Signorelli D, Pappagallo G, Ricardi U, Collaborators
doi: 10.1016/j.lungcan.2025.108807
RECOMMENDED
Interstitial Lung Disease
Clinical utility of lung biopsy in fibrotic interstitial lung disease
★ 3
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Mor E, Piciucchi S, Ravaglia C, Aronson K, Poletti V, Hariri LP, Khor YH, Churg A, Collins B, Fabre A, Adegunsoye A, Chung J, Cooper WA, Cottin V, Dotan Y, Hague C, Inoue Y, Jacob J, Martinez F, Podolanczuk AJ, Tomassetti S, Wells AU, Wijsenbeek MS, Yasufuku K, Dominy L, Mcdonald J, Sangari S, Ryerson CJ
doi: 10.1093/ajrccm/aamaf123
RECOMMENDED
Lung Cancer
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur J Cancer
Matsumoto K, Yamamoto Y, Shiroyama T, Kuge T, Miyazaki A, Komuta K, Tamiya M, Nishino K, Tsukaguchi A, Tamiya A, Mihashi Y, Uchida J, Mori M, Yamauchi K, Suzuki H, Kinehara Y, Moritomo K, Shoshihara N, Machiyama H, Kanaoka K, Tobita S, Ueno K, Niki T, Tetsumoto S, Nishikawa Y, Morimura O, Kato S, Yoneda M, Azuma K, Osa A, Minami T, Nagatomo I, Takeda Y, Kumanogoh A
doi: 10.1016/j.ejca.2026.116902
Lung Cancer
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
Lung Cancer
Zhou DD, Lord SJ, Lin FP, Cooper WA, Zaheed M, Simes RJ, John T, Lee CK
doi: 10.1016/j.lungcan.2025.108891
RECOMMENDED
Interstitial Lung Disease
Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines into Clinical Practice
★ 3
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Esposito AJ, Selvan KC, Richardson C, Khanna D, Bemiss BC, Bernstein EJ, Chung JH, Cox CW, Dematte JE, Denton CP, Distler O, Hinchcliff ME, Smith V, Strek ME, Varga J, Hoffmann-Vold AM, Volkmann ER
doi: 10.1016/j.chest.2025.11.047